查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
先進藥物遞輸系統的全球市場(2022年～2026年)
市場調查報告書
商品編碼
1066591

先進藥物遞輸系統的全球市場(2022年～2026年)

Global Advanced Drug Delivery Systems Market 2022-2026
出版日期: | 出版商: TechNavio | 英文 120 Pages | 訂單完成後即時交付

價格
簡介目錄

全球先進藥物遞輸系統的市場規模在2022年～2026年間，預測將成長到917億9,000萬美元，在預測期間內預計將以年複合成長率7.41％緩慢的成長。市場成長的主要因素有慢性疾病，藥物輸送的研究開發的投資增加等。

本報告提供全球先進藥物遞輸系統市場相關調查分析，網羅整體分析，市場規模·預測，趨勢，成長促進因素，課題，及約25公司的供應商分析等資訊。

目錄

第1章 摘要整理

  • 市場概要

第2章 市場形勢

  • 市場生態系統
  • 價值鏈分析

第3章 市場規模

  • 市場定義
  • 市場區隔分析
  • 市場規模:2021年
  • 市場預測:2021年～2026年的預測

第4章 波特的五力分析

  • 五力的摘要
  • 買方議價能力
  • 供給企業談判力
  • 新加入廠商業者帶來的威脅
  • 替代品帶來的威脅
  • 對手業者帶來的威脅
  • 市場情況

第5章 市場區隔:各類型

  • 市場區隔
  • 比較:各類型
  • 口服 - 市場規模與預測(2021年～2026年)
  • 注射與吸入 - 市場規模與預測(2021年～2026年)
  • 經皮 - 市場規模與預測(2021年～2026年)
  • 基於載體 - 市場規模與預測(2021年～2026年)
  • 其他 - 市場規模與預測(2021年～2026年)
  • 市場機會:各類型

第6章 客戶形勢

  • 概要

第7章 各地區形勢

  • 地區市場區隔
  • 地區比較 - 市場規模與預測(
  • 北美 - 市場規模與預測(2021年～2026年)
  • 歐洲 - 市場規模與預測(2021年～2026年)
  • 亞洲 - 市場規模與預測(2021年～2026年)
  • 其他地區 - 市場規模與預測(2021年～2026年)
  • 主要國家
  • 市場機會:各地區形勢

第8章 促進因素，課題，及趨勢

  • 推動市場要素
  • 市場課題
  • 市場趨勢

第9章 業者情勢

  • 概要
  • 混亂狀況

第10章 供應商分析

  • 交易廠商
  • 供應商的市場定位
  • 3M Co.
  • Alkermes Public Co. Ltd.
  • Antares Pharma Inc.
  • Baxter International Inc.
  • Becton Dickinson and Co.
  • Endo International Plc
  • NanoPass Technologies Ltd.
  • Nektar Therapeutics
  • Perrigo Co. Plc
  • Teva Pharmaceutical Industries Ltd.

第11章 附錄

簡介目錄
Product Code: IRTNTR72271

Technavio has been monitoring the advanced drug delivery systems market and it is poised to grow by $ 91.79 bn during 2022-2026 decelerating at a CAGR of 7.41% during the forecast period. Our report on advanced drug delivery systems market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by rising chronic diseases and rising investment in research and development of drug delivery.

The advanced drug delivery systems market analysis includes the type segment and geographic landscape.

Technavio's advanced drug delivery systems market is segmented as below:

By Type

  • Oral
  • Injection and inhalation
  • Transdermal
  • Carrier-based
  • Others

By Geographical Landscape

  • North America
  • Europe
  • Asia
  • ROW

This study identifies the rising healthcare expenditure globallyas one of the prime reasons driving the advanced drug delivery systems market growth during the next few years.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters. Our report on advanced drug delivery systems market covers the following areas:

  • Advanced drug delivery systems market sizing
  • Advanced drug delivery systems market forecast
  • Advanced drug delivery systems market industry analysis

Technavio's robust vendor analysis is designed to help clients improve their market position, and in line with this, this report provides a detailed analysis of several leading advanced drug delivery systems market vendors that include 3M Co., Alkermes Public Co. Ltd., Antares Pharma Inc., Baxter International Inc., Becton Dickinson and Co., Endo International Plc, NanoPass Technologies Ltd., Nektar Therapeutics, Perrigo Co. Plc, and Teva Pharmaceutical Industries Ltd. Also, the advanced drug delivery systems market analysis report includes information on upcoming trends and challenges that will influence market growth. This is to help companies strategize and leverage all forthcoming growth opportunities.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavio's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast the accurate market growth.

Table of Contents

1. Executive Summary

  • 1.1 Market Overview
  • Exhibit 01: Key Finding 1
  • Exhibit 02: Key Finding 2
  • Exhibit 03: Key Finding 3
  • Exhibit 04: Key Finding 5
  • Exhibit 05: Key Finding 6
  • Exhibit 06: Key Finding 7
  • Exhibit 07: Key Finding 8

2. Market Landscape

  • 2.1 Market ecosystem
  • Exhibit 08: Parent market
  • Exhibit 09: Market Characteristics
  • 2.2 Value chain analysis
  • Exhibit 10: Value chain analysis: Life Sciences Tools and Services
    • 2.2.1 Research and development
    • 2.2.2 Inputs
    • 2.2.3 Production
    • 2.2.4 Distribution
    • 2.2.5 Marketing and sales
    • 2.2.6 Post-sales and services
    • 2.2.7 Industry innovations

3. Market Sizing

  • 3.1 Market definition
  • Exhibit 11: Offerings of vendors included in the market definition
  • 3.2 Market segment analysis
  • Exhibit 12: Market segments
  • 3.3 Market size 2021
  • 3.4 Market outlook: Forecast for 2021 - 2026
    • 3.4.1 Estimating growth rates for emerging and high-growth markets
    • 3.4.2 Estimating growth rates for mature markets
  • Exhibit 13: Global - Market size and forecast 2021 - 2026 ($ billion)
  • Exhibit 14: Global market: Year-over-year growth 2021 - 2026 (%)

4. Five Forces Analysis

  • 4.1 Five Forces Summary
  • Exhibit 15: Five forces analysis 2021 & 2026
  • 4.2 Bargaining power of buyers
  • Exhibit 16: Bargaining power of buyers
  • 4.3 Bargaining power of suppliers
  • Exhibit 17: Bargaining power of suppliers
  • 4.4 Threat of new entrants
  • Exhibit 18: Threat of new entrants
  • 4.5 Threat of substitutes
  • Exhibit 19: Threat of substitutes
  • 4.6 Threat of rivalry
  • Exhibit 20: Threat of rivalry
  • 4.7 Market condition
  • Exhibit 21: Market condition - Five forces 2021

5. Market Segmentation by Type

  • 5.1 Market segments
    • The segments covered in this chapter are:
  • o Oral
  • o Injection and inhalation
  • o Transdermal
  • o Carrier-based
  • o Others
  • Exhibit 22: Type - Market share 2021-2026 (%)
  • 5.2 Comparison by Type
  • Exhibit 23: Comparison by Type
  • 5.3 Oral - Market size and forecast 2021-2026
  • Exhibit 24: Oral - Market size and forecast 2021-2026 ($ billion)
  • Exhibit 25: Oral - Year-over-year growth 2021-2026 (%)
  • 5.4 Injection and inhalation - Market size and forecast 2021-2026
  • Exhibit 26: Injection and inhalation - Market size and forecast 2021-2026 ($ billion)
  • Exhibit 27: Injection and inhalation - Year-over-year growth 2021-2026 (%)
  • 5.5 Transdermal - Market size and forecast 2021-2026
  • Exhibit 28: Transdermal - Market size and forecast 2021-2026 ($ billion)
  • Exhibit 29: Transdermal - Year-over-year growth 2021-2026 (%)
  • 5.6 Carrier-based - Market size and forecast 2021-2026
  • Exhibit 30: Carrier-based - Market size and forecast 2021-2026 ($ billion)
  • Exhibit 31: Carrier-based - Year-over-year growth 2021-2026 (%)
  • 5.7 Others - Market size and forecast 2021-2026
  • Exhibit 32: Others - Market size and forecast 2021-2026 ($ billion)
  • Exhibit 33: Others - Year-over-year growth 2021-2026 (%)
  • 5.8 Market opportunity by Type
  • Exhibit 34: Market opportunity by Type

6. Customer landscape

  • 6.1 Overview
  • Exhibit 35: Customer landscape

7. Geographic Landscape

  • 7.1 Geographic segmentation
    • The regions covered in the report are:
  • o North America
  • o Europe
  • o Asia
  • o ROW
  • Exhibit 36: Market share By Geographical Landscape 2021-2026 (%)
  • 7.2 Geographic comparison
  • Exhibit 37: Geographic comparison
  • 7.3 North America - Market size and forecast 2021-2026
  • Exhibit 38: North America - Market size and forecast 2021-2026 ($ billion)
  • Exhibit 39: North America - Year-over-year growth 2021-2026 (%)
  • 7.4 Europe - Market size and forecast 2021-2026
  • Exhibit 40: Europe - Market size and forecast 2021-2026 ($ billion)
  • Exhibit 41: Europe - Year-over-year growth 2021-2026 (%)
  • 7.5 Asia - Market size and forecast 2021-2026
  • Exhibit 42: Asia - Market size and forecast 2021-2026 ($ billion)
  • Exhibit 43: Asia - Year-over-year growth 2021-2026 (%)
  • 7.6 ROW - Market size and forecast 2021-2026
  • Exhibit 44: ROW - Market size and forecast 2021-2026 ($ billion)
  • Exhibit 45: ROW - Year-over-year growth 2021-2026 (%)
  • 7.7 Key leading countries
  • Exhibit 46: Key leading countries
  • 7.9 Market opportunity By Geographical Landscape
  • Exhibit 47: Market opportunity By Geographical Landscape ($ billion)

8. Drivers, Challenges, and Trends

  • 8.1 Market drivers
    • 8.1.1 Rising chronic diseases
    • 8.1.2 Rising investment in research and development of drug delivery
    • 8.1.3 Rising healthcare expenditure globally
  • 8.2 Market challenges
    • 8.2.1 Presence of stringent regulations
    • 8.2.2 Poor healthcare infrastructure in underdeveloped or developing countries
    • 8.2.3 Biocompatibility and acceptability with human body
  • Exhibit 48: Impact of drivers and challenges
  • 8.3 Market trends
    • 8.3.1 Covid-19 pandemic to create multiple opportunities in the market
    • 8.3.2 Introduction of targeted drug delivery system
    • 8.3.3 Reduced side effects

9. Vendor Landscape

  • 9.1 Overview
  • Exhibit 49: Vendor landscape
  • 9.2 Landscape disruption
  • Exhibit 50: Landscape disruption
  • Exhibit 51: Industry risks

10. Vendor Analysis

  • 10.1 Vendors covered
  • Exhibit 52: Vendors covered
  • 10.2 Market positioning of vendors
  • Exhibit 53: Market positioning of vendors
  • 10.3 3M Co.
  • Exhibit 54: 3M Co. - Overview
  • Exhibit 55: 3M Co. - Business segments
  • Exhibit 56: 3M Co. - Key offerings
  • Exhibit 57: 3M Co. - Segment focus
  • 10.4 Alkermes Public Co. Ltd.
  • Exhibit 58: Alkermes Public Co. Ltd. - Overview
  • Exhibit 59: Alkermes Public Co. Ltd. - Business segments
  • Exhibit 60: Alkermes Public Co. Ltd. - Key news
  • Exhibit 61: Alkermes Public Co. Ltd. - Key offerings
  • 10.5 Antares Pharma Inc.
  • Exhibit 62: Antares Pharma Inc. - Overview
  • Exhibit 63: Antares Pharma Inc. - Business segments
  • Exhibit 64: Antares Pharma Inc. - Key news
  • Exhibit 65: Antares Pharma Inc. - Key offerings
  • 10.6 Baxter International Inc.
  • Exhibit 66: Baxter International Inc. - Overview
  • Exhibit 67: Baxter International Inc. - Business segments
  • Exhibit 68: Baxter International Inc. - Key offerings
  • Exhibit 69: Baxter International Inc. - Segment focus
  • 10.7 Becton Dickinson and Co.
  • Exhibit 70: Becton Dickinson and Co. - Overview
  • Exhibit 71: Becton Dickinson and Co. - Business segments
  • Exhibit 72: Becton Dickinson and Co. - Key offerings
  • Exhibit 73: Becton Dickinson and Co. - Segment focus
  • 10.8 Endo International Plc
  • Exhibit 74: Endo International Plc - Overview
  • Exhibit 75: Endo International Plc - Business segments
  • Exhibit 76: Endo International Plc. - Key news
  • Exhibit 77: Endo International Plc - Key offerings
  • Exhibit 78: Endo International Plc - Segment focus
  • 10.9 NanoPass Technologies Ltd.
  • Exhibit 79: NanoPass Technologies Ltd. - Overview
  • Exhibit 80: NanoPass Technologies Ltd. - Product and service
  • Exhibit 81: NanoPass Technologies Ltd. - Key offerings
  • 10.10 Nektar Therapeutics
  • Exhibit 82: Nektar Therapeutics - Overview
  • Exhibit 83: Nektar Therapeutics - Product and service
  • Exhibit 84: Nektar Therapeutics - Key offerings
  • 10.11 Perrigo Co. Plc
  • Exhibit 85: Perrigo Co. Plc - Overview
  • Exhibit 86: Perrigo Co. Plc - Business segments
  • Exhibit 87: Perrigo Co. Plc - Key offerings
  • Exhibit 88: Perrigo Co. Plc - Segment focus
  • 10.12 Teva Pharmaceutical Industries Ltd.
  • Exhibit 89: Teva Pharmaceutical Industries Ltd. - Overview
  • Exhibit 90: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibit 91: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibit 92: Teva Pharmaceutical Industries Ltd. - Segment focus

11. Appendix

  • 11.1 Scope of the report
    • 11.1.1 Market definition
    • 11.1.2 Objective
    • 11.1.3 Notes and caveats
  • 11.2 Currency conversion rates for US$
  • Exhibit 93: Currency conversion rates for US$
  • 11.3 Research Methodology
  • Exhibit 94: Research Methodology
  • Exhibit 95: Validation techniques employed for market sizing
  • Exhibit 96: Information sources
  • 11.4 List of abbreviations
  • Exhibit 97: List of abbreviations

Exhibits

  • Exhibits1: Key Finding 1
  • Exhibits2: Key Finding 2
  • Exhibits3: Key Finding 3
  • Exhibits4: Key Finding 5
  • Exhibits5: Key Finding 6
  • Exhibits6: Key Finding 7
  • Exhibits7: Key Finding 8
  • Exhibits8: Parent market
  • Exhibits9: Market characteristics
  • Exhibits10: Offerings of vendors included in the market definition
  • Exhibits11: Market segments
  • Exhibits12: Global - Market size and forecast 2021 - 2026 ($ billion)
  • Exhibits13: Global market: Year-over-year growth 2021 - 2026 (%)
  • Exhibits14: Five forces analysis 2021 & 2026
  • Exhibits15: Bargaining power of buyers
  • Exhibits16: Bargaining power of suppliers
  • Exhibits17: Threat of new entrants
  • Exhibits18: Threat of substitutes
  • Exhibits19: Threat of rivalry
  • Exhibits20: Market condition - Five forces 2021
  • Exhibits21: Type - Market share 2021-2026 (%)
  • Exhibits22: Comparison by Type
  • Exhibits23: Oral - Market size and forecast 2021-2026 ($ billion)
  • Exhibits24: Oral - Year-over-year growth 2021-2026 (%)
  • Exhibits25: Injection and inhalation - Market size and forecast 2021-2026 ($ billion)
  • Exhibits26: Injection and inhalation - Year-over-year growth 2021-2026 (%)
  • Exhibits27: Transdermal - Market size and forecast 2021-2026 ($ billion)
  • Exhibits28: Transdermal - Year-over-year growth 2021-2026 (%)
  • Exhibits29: Carrier-based - Market size and forecast 2021-2026 ($ billion)
  • Exhibits30: Carrier-based - Year-over-year growth 2021-2026 (%)
  • Exhibits31: Others - Market size and forecast 2021-2026 ($ billion)
  • Exhibits32: Others - Year-over-year growth 2021-2026 (%)
  • Exhibits33: Market opportunity by Type
  • Exhibits34: Customer landscape
  • Exhibits35: Market share By Geographical Landscape 2021-2026 (%)
  • Exhibits36: Geographic comparison
  • Exhibits37: North America - Market size and forecast 2021-2026 ($ billion)
  • Exhibits38: North America - Year-over-year growth 2021-2026 (%)
  • Exhibits39: Europe - Market size and forecast 2021-2026 ($ billion)
  • Exhibits40: Europe - Year-over-year growth 2021-2026 (%)
  • Exhibits41: Asia - Market size and forecast 2021-2026 ($ billion)
  • Exhibits42: Asia - Year-over-year growth 2021-2026 (%)
  • Exhibits43: ROW - Market size and forecast 2021-2026 ($ billion)
  • Exhibits44: ROW - Year-over-year growth 2021-2026 (%)
  • Exhibits45: Key leading countries
  • Exhibits46: Market opportunity By Geographical Landscape ($ billion)
  • Exhibits47: Impact of drivers and challenges
  • Exhibits48: Vendor landscape
  • Exhibits49: Landscape disruption
  • Exhibits50: Industry risks
  • Exhibits51: Vendors covered
  • Exhibits52: Market positioning of vendors
  • Exhibits53: 3M Co. - Overview
  • Exhibits54: 3M Co. - Business segments
  • Exhibits55: 3M Co. - Key offerings
  • Exhibits56: 3M Co. - Key customers
  • Exhibits57: 3M Co. - Segment focus
  • Exhibits58: Alkermes Public Co. Ltd. - Overview
  • Exhibits59: Alkermes Public Co. Ltd. - Business segments
  • Exhibits60: Alkermes Public Co. Ltd. - Key offerings
  • Exhibits61: Alkermes Public Co. Ltd. - Key customers
  • Exhibits62: Alkermes Public Co. Ltd. - Segment focus
  • Exhibits63: Antares Pharma Inc. - Overview
  • Exhibits64: Antares Pharma Inc. - Business segments
  • Exhibits65: Antares Pharma Inc. - Key offerings
  • Exhibits66: Antares Pharma Inc. - Key customers
  • Exhibits67: Antares Pharma Inc. - Segment focus
  • Exhibits68: Baxter International Inc. - Overview
  • Exhibits69: Baxter International Inc. - Business segments
  • Exhibits70: Baxter International Inc. - Key offerings
  • Exhibits71: Baxter International Inc. - Key customers
  • Exhibits72: Baxter International Inc. - Segment focus
  • Exhibits73: Becton Dickinson and Co. - Overview
  • Exhibits74: Becton Dickinson and Co. - Business segments
  • Exhibits75: Becton Dickinson and Co. - Key offerings
  • Exhibits76: Becton Dickinson and Co. - Key customers
  • Exhibits77: Becton Dickinson and Co. - Segment focus
  • Exhibits78: Endo International Plc - Overview
  • Exhibits79: Endo International Plc - Business segments
  • Exhibits80: Endo International Plc - Key offerings
  • Exhibits81: Endo International Plc - Key customers
  • Exhibits82: Endo International Plc - Segment focus
  • Exhibits83: NanoPass Technologies Ltd. - Overview
  • Exhibits84: NanoPass Technologies Ltd. - Product and service
  • Exhibits85: NanoPass Technologies Ltd. - Key offerings
  • Exhibits86: NanoPass Technologies Ltd. - Key customers
  • Exhibits87: NanoPass Technologies Ltd. - Segment focus
  • Exhibits88: Nektar Therapeutics - Overview
  • Exhibits89: Nektar Therapeutics - Product and service
  • Exhibits90: Nektar Therapeutics - Key offerings
  • Exhibits91: Nektar Therapeutics - Key customers
  • Exhibits92: Nektar Therapeutics - Segment focus
  • Exhibits93: Perrigo Co. Plc - Overview
  • Exhibits94: Perrigo Co. Plc - Business segments
  • Exhibits95: Perrigo Co. Plc - Key offerings
  • Exhibits96: Perrigo Co. Plc - Key customers
  • Exhibits97: Perrigo Co. Plc - Segment focus
  • Exhibits98: Teva Pharmaceutical Industries Ltd. - Overview
  • Exhibits99: Teva Pharmaceutical Industries Ltd. - Business segments
  • Exhibits100: Teva Pharmaceutical Industries Ltd. - Key offerings
  • Exhibits101: Teva Pharmaceutical Industries Ltd. - Key customers
  • Exhibits102: Teva Pharmaceutical Industries Ltd. - Segment focus
  • Exhibits103: Currency conversion rates for US$
  • Exhibits104: Research Methodology
  • Exhibits105: Validation techniques employed for market sizing
  • Exhibits106: Information sources
  • Exhibits107: List of abbreviations